UPDATE: AO-252 Demonstrates 80% Clinical Benefit Rate as Development Shifts to Expansion Phase

AO-252, a first-in-class TACC3 inhibitor, continues to show early clinical promise in advanced solid tumours, with recent updates highlighting both improved efficacy through optimized dosing and a new formulation designed to enhance drug exposure.

Interim data from an ongoing Phase 1/2 trial demonstrated a clear dosing-dependent effect. Transitioning from once-daily (QD) to twice-daily (BID) administration increased the clinical benefit rate (CBR) from 40% to 80% in heavily pre-treated patients. Tumour stabilisation or regression was observed in the majority of evaluable patients receiving BID dosing, with several responses extending beyond six months, exceeding the typical 2–3 month duration expected in salvage settings. The treatment has also shown a favorable safety profile, with no serious adverse events reported to date. Mechanistically, AO-252 is notable for its dual activity, combining direct cytotoxic effects with activation of the cGAS/STING pathway, suggesting potential synergy with immunotherapy approaches.

Building on these findings, a next-generation lipid-based softgel formulation of AO-252 is now entering clinical use, with first patient dosing expected in July 2026. The updated formulation is designed to overcome pharmacokinetic limitations seen with the current tablet version, which exhibits dose-dependent absorption constraints and variability at higher doses. By delivering AO-252 in a pre-dissolved lipid system, the new approach aims to achieve more consistent, dose-proportional exposure and improve overall drug uptake.

This formulation optimization comes as the program transitions into targeted dose expansion cohorts in ovarian and prostate cancers, with enrolment expected to reach up to 30–40 patients by late 2026. The previously observed 80% CBR with BID dosing provides a strong rationale for enhancing exposure as development advances. If improved pharmacokinetics translate into deeper or more durable responses, AO-252 could represent a differentiated small molecule with both cytotoxic and immune-modulating properties in difficult-to-treat cancers.

Clinical trial.